

Professor Emeritus Yechezkel (Chezy) Barenholz

Professor Emeritus Yechezkel (Chezy) Barenholz is head of the Liposome and Membrane Research Lab at the Hebrew University-Hadassah Medical School, Jerusalem, Israel and is also the Daniel G. Miller Professor in Cancer Research at Hebrew University of Jerusalem. He has been on the faculty at Hebrew University since 1968 and has been a visiting Professor at leading Universities around the world. His current research focuses on the development of drugs and nano-drugs based on drug delivery systems (DDS) best exemplified by the anticancer Doxil®, the first liposomal drug as well as the first nano-drug approved by the FDA (1995) and used world-wide. Professor Barenholz is an author of >400 scientific publications and is a co-inventor in > 45 approved patent families. He is a founder of four 5 start-ups, NasVax (now Therapix) Moebious, PolyPid, LipoCureRX, and Ayana. He received many National and International awards including Honorary Doctorate degree from the Technical University of Denmark (2012) and the 2012 founders award of the International Controlled Release Society. In 2003, Professor Barenholz founded the Barenholz Prizes from Doxil® royalties to encourage excellence and innovation in the applied sciences of Israeli PhD students. Professor Barenholz is married to Dr Hanna Barenholz together they have 4 daughters and 12 grandchildren.